Literature DB >> 8652852

Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells.

D A Breems1, P B van Hennik, N Kusadasi, A Boudewijn, J J Cornelissen, P Sonneveld, R E Ploemacher.   

Abstract

Peripheral blood stem cells (PBSC) are used for stem cell support in patients after intensive chemotherapy and generally permit faster hematopoietic recovery than bone marrow. The development of different protocols for chemotherapy conditioning, mobilization, and ex vivo manipulation of PBSC may potentially lead to loss of primitive hematopoietic stem cells or reduction of their quality. To characterize the frequency of different stem cell subsets and their quality per mobilized PBSC, we have studied 47 leukapheresis products (LPs) of 21 cancer patients using stroma-dependent long-term culture (LTC) and limiting dilution-type cobblestone area forming cell (CAFC) assays. A large variation in CAFC week-type frequencies between the LPs was observed. The frequencies of CAFC week 2 as a tentative indicator of progenitor cells and transiently repopulating hematopoietic stem cells ranged from 0.89 to 205 per 10(5) mobilized nucleated cells and the frequencies of more primitive CAFC week 6 varied between 0.37 and 48. The average total colony-forming cell (CFC) production per CAFC at week 6 varied between 1.2 and 730, as determined in parallel LTC. In contrast to LPs, bone marrow samples generated 4.2 to 48 CFC per CAFC at week 6. Notably, a poor stem cell quality was consistently found in LPs that contained less than 5,000 CAFC week 6 per kilogram of body weight. Frequency analyses of CFCs, CAFC subtypes, and immunophenotypic subsets showed a good level of mutual correlation, suggesting identical mobilization kinetics of different stem cell subsets. The premobilization chemotherapy intensity was directly correlated with both decreasing frequency and quality of the CAFC week 6 in LPs. The frequency of CFCs, immunophenotypic subsets, and CAFC subsets transplanted and the transplant quality as determined in LTC assays was related to the neutrophil and platelet recovery time after PBSC transplantation. Although the number of progenitor cells transplanted and the in vitro transplant quality showed the best correlation with early hematopoietic recovery, the data did not permit determination of which stem cell subsets are predominantly responsible for early posttransplantation recovery. As a result, frequency and quality analysis of stem cell subsets may be a useful tool to monitor and calibrate the efficacy of novel mobilization regimens and ex vivo manipulation of PBSC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652852

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  On how Rac controls hematopoietic stem cell activity.

Authors:  J A Cancelas
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

2.  Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization.

Authors:  Marnie A Ryan; Kalpana J Nattamai; Ellen Xing; David Schleimer; Deidre Daria; Amitava Sengupta; Anja Köhler; Wei Liu; Matthias Gunzer; Michael Jansen; Nancy Ratner; Timothy D Le Cras; Amanda Waterstrat; Gary Van Zant; Jose A Cancelas; Yi Zheng; Hartmut Geiger
Journal:  Nat Med       Date:  2010-09-26       Impact factor: 53.440

3.  Stem cells from birth to death: The history and the future.

Authors:  Gerald de Haan; Gary Van Zant
Journal:  J Am Aging Assoc       Date:  2002-04

4.  Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo.

Authors:  A Olivieri; M Marchetti; R Lemoli; C Tarella; A Iacone; F Lanza; A Rambaldi; A Bosi
Journal:  Bone Marrow Transplant       Date:  2011-05-30       Impact factor: 5.483

5.  Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer.

Authors:  P Pedrazzoli; C Perotti; G A Da Prada; F Bertolini; N Gibelli; L Torretta; M Battaglia; L Pavesi; P Preti; L Salvaneschi; G Robustelli della Cuna
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.